<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Levodopa and benserazide (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Levodopa and benserazide (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Levodopa and benserazide (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11816" href="/d/html/11816.html" rel="external">see "Levodopa and benserazide (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866040"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Prolopa 100-25;</li>
<li>Prolopa 200-50;</li>
<li>Prolopa 50-12.5</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F139728"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anti-Parkinson Agent, Dopamine Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F139721"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="afdbcf58-54a4-4f1f-8310-d12811c549e2">Parkinson disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease: Adults ≥25 years of age: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dosage should be introduced gradually, individualized, and continued for 3 to 6 weeks before assessing benefit. Available formulations include benserazide 25 mg/levodopa 100 mg, benserazide 50 mg/levodopa 200 mg, and benserazide 12.5 mg/levodopa 50 mg. Benserazide 50 mg/levodopa 200 mg formulations should be used only when maintenance therapy is reached. Benserazide 12.5 mg/levodopa 50 mg formulations should be used to minimize adverse effects when adjusting dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initiation: Benserazide 25 mg/levodopa 100 mg once or twice daily; increase dose by benserazide 25 mg/levodopa 100 mg every 3 to 4 days or slower (eg, weekly) if problems with tolerance until adequate therapeutic effect without dyskinesias; reduce frequency of dosage adjustments to every 2 to 4 weeks as upper limits of dosing range is approached.</p>
<p style="text-indent:-2em;margin-left:6em;">Usual maintenance dosage: Benserazide 100 mg/levodopa 400 mg to benserazide 200 mg/levodopa 800 mg daily given in 4 to 6 divided doses; after maintenance dose of benserazide/levodopa is established, slowly decrease dose of levodopa by 50 mg per month over a few months until a maintenance dose without dyskinesias is achieved.</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum: Total daily dose of levodopa during the first year of therapy should not exceed 1,000 mg to 1,200 mg/day. Following first year, the maximum recommended daily dose of levodopa is 600 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="be43cdd3-ce21-4fc1-aab2-7b1bf1338876">Restless legs syndrome, intermittent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Restless legs syndrome, intermittent (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: Due to risk of augmentation (worsening symptoms during dopaminergic therapy), limit frequency to 2 to 3 administrations per week. May also be taken as needed prior to specific restless legs syndrome triggers, such as prolonged immobility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27448465']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27448465'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: Benserazide 25 mg/levodopa 100 mg as needed before bedtime; may increase to benserazide 50 mg/levodopa 200 mg based on response and tolerability. Maximum: levodopa 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10617168','lexi-content-ref-22937989']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10617168','lexi-content-ref-22937989'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy</b>: Discontinuation of therapy may result in neuroleptic malignant-like syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31501181','lexi-content-ref-12573874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31501181','lexi-content-ref-12573874'])">Ref</a></span>). Avoid sudden discontinuation or rapid dose reduction; some experts recommend a gradual taper over several weeks or more (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Oliver.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Oliver.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990779"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling. Use in decompensated renal disease is contraindicated.</p></div>
<div class="block doha drugH1Div" id="F50987954"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling. Use in decompensated hepatic disease is contraindicated.</p></div>
<div class="block dot drugH1Div" id="F46730696"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Patients experiencing dystonia:</b> There are no specific dosage recommendations provided in the manufacturer’s labeling however a levodopa dose reduction is recommended; may also consider adjusting the dosing frequency. <b>Note:</b> Dystonias may appear earlier in benserazide/levodopa therapy than with levodopa alone.</p></div>
<div class="block doe drugH1Div" id="F2564095"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F139685"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults. Also see levodopa monograph.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Involuntary body movements (≥30%; including athetosis, choreiform movements, dystonia), psychiatric disturbance (20%; including dementia, depression [including depression with suicidal tendencies], paranoid ideation, psychotic reaction)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris, cardiac arrhythmias, ECG changes (nonspecific), edema, flushing, hypertension, orthostatic hypotension, phlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatological: Alopecia, dark sweat, diaphoresis, pallor, pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Change in libido (including increased libido with serious antisocial behavior), increased lactate dehydrogenase, increased protein-bound iodine, increased uric acid, weight changes</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, abdominal pain, ageusia, anorexia, bitter taste, bruxism, constipation, diarrhea, discoloration of saliva, duodenal ulcer, dysphagia, epigastric discomfort, epigastric pain, eructation, flatulence, gastrointestinal hemorrhage, hiccups, nausea, oral mucosa changes (discoloration and staining), sialorrhea, staining of tooth, tongue discoloration, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria, nocturia, urinary frequency, urinary incontinence, urinary retention, urine discoloration (including dark urine)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, hemolytic anemia, leukopenia, positive direct Coombs' test, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait, agitation, akinesia (end of dose and akinesia paradoxica), anxiety, asthenia, ataxia, confusion, daytime sedation, delusion, disorientation, dizziness, dopamine dysregulation syndrome, drowsiness, euphoria, fatigue, glosspyrosis, hallucination, headache, Horner syndrome (activation of latent), insomnia, lethargy, malaise, nightmares, numbness, on-off phenomenon, sedated state, seizure, sensation of tightness (mouth, lips, tongue), sense of stimulation, sleep driving, sudden onset of sleep, trismus</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia, lower back pain, lupus-like syndrome (Massarotti 1979), muscle spasm, muscle twitching, musculoskeletal pain, torticollis, tremor of hands (increased)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharospasm, blurred vision, diplopia, mydriasis, oculogyric crisis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, hoarseness, irregular breathing, post nasal drip</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F139700"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to benserazide, levodopa, or any component of the formulation; use with or within 14 days of MAO inhibitors; when administration of a sympathomimetic amine (eg, epinephrine, norepinephrine, isoproterenol) is contraindicated; clinical or laboratory evidence of decompensated cardiovascular, endocrine, renal, hepatic, hematologic, or pulmonary disease; psychiatric diseases with a psychotic component; angle-closure glaucoma; patients &lt;25 years of age; pregnancy or use in women of childbearing potential without adequate contraception</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F139683"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: <b>[Canadian Boxed Warning]: Patients have reported falling asleep while engaging in activities of daily living including the driving of a car; in some cases, these events have occurred without significant warning signs.</b> Monitor for daytime somnolence or preexisting sleep disorder; discontinue if significant daytime sleepiness or episodes of falling asleep occur. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Use with caution in patients receiving other CNS depressants or psychoactive agents. Effects with other sedative drugs or ethanol may be potentiated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions may occur in susceptible patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Impulse control disorders: Dopamine agonists used for Parkinson disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/substance use disorders and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased growth hormone levels: May increase human growth hormone levels.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (MI, atrial, nodal, or ventricular arrhythmias); initiate in a monitored setting. Use is contraindicated in decompensated cardiovascular disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; monitor blood glucose frequently. Antidiabetic agents may require dose adjustment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with chronic wide-angle glaucoma; monitor IOP carefully. Use is contraindicated in patients with angle-closure glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Use is contraindicated in decompensated hepatic disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peptic ulcer disease: Use with caution in patients with peptic ulcer disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychotic disorders: Use with extreme caution in patients with a history of psychotic disorders; observe patients closely for development of depression with concomitant suicidal tendencies. May also cause hallucinations and confusion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Use is contraindicated in decompensated renal disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a history of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; may be more sensitive to CNS effects of levodopa.</p>
<p style="text-indent:-2em;margin-left:4em;">• Perioperative patients: Continue therapy as close to surgical procedures as possible in patients requiring general anesthesia (excluding halothane-risk of blood pressure fluctuations and/or arrhythmias; discontinue benserazide/levodopa 12 to 48 hours before procedure); resume therapy postoperatively with a gradual increase in dose up to that established preoperatively.</p>
<p style="text-indent:-2em;margin-left:4em;">• Young adults: Use is contraindicated in patients &lt;25 years of age. Animal data suggests the possibility of skeletal abnormalities if benserazide is administered before ossification is complete.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse: May induce dopaminergic dysregulation syndrome resulting in excessive use of benserazide/levodopa beyond prescribed doses, particularly in males with early onset Parkinson disease (Giovannoni 2000); may lead to cognitive and behavioral disturbances. Monitor for excessive use if cognitive/behavioral disturbances develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not indicated in management of intention tremor, Huntington's chorea, or drug-induced extrapyramidal symptoms. Administer in careful increments and observe closely for development of abnormal involuntary movements.</p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Avoid abrupt withdrawal of therapy; dopaminergic agents have been associated with a syndrome resembling neuroleptic malignant syndrome (NMS) on abrupt withdrawal or significant dosage reduction after long-term use. Withdraw therapy gradually and monitor closely; symptomatic patients should be treated appropriately and if necessary resumption of benserazide/levodopa therapy may be considered.</p></div>
<div class="block prod-avail drugH1Div" id="F11217268"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the United States.</p></div>
<div class="block geq drugH1Div" id="F52917357"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52866041"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prolopa 100-25: levodopa 100 mg and benserazide 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prolopa 200-50: levodopa 200 mg and benserazide 50 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prolopa 50-12.5: levodopa 50 mg and benserazide 12.5 mg</p></div>
<div class="block adm drugH1Div" id="F139697"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or immediately after a non-protein or low-protein snack (eg, fruit, applesauce, biscuits) to control GI side effects. Capsules should be swallowed whole; do not crush, chew, open, or dissolve in liquid.</p></div>
<div class="block use drugH1Div" id="F139696"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease: </b>Treatment of Parkinson disease (except drug-induced Parkinsonism)</p></div>
<div class="block off-label drugH1Div" id="F56512988"><span class="drugH1">Use: Off-Label: Adult</span><p>Parkinsonism (including corticobasal degeneration, dementia with Lewy bodies, drug-induced parkinsonism, multiple system atrophy, and progressive supranuclear palsy); Restless legs syndrome, intermittent</p></div>
<div class="block mst drugH1Div" id="F26116829"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298828"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F139687"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Injection): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Amisulpride (Oral). Amisulpride (Oral) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (First Generation [Typical]): Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). Antipsychotic Agents (First Generation [Typical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Avoid concomitant therapy if possible. If antipsychotic use is necessary, consider using atypical antipsychotics such as clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Consider avoiding atypical antipsychotic use in patients with Parkinson disease. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Biperiden: May enhance the adverse/toxic effect of Levodopa-Foslevodopa. Specifically, the risk of choreic movements or dyskinesias may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Levodopa-Foslevodopa.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist). Specifically, the risk of chorea may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: Anti-Parkinson Agents (Dopamine Agonist) may enhance the adverse/toxic effect of BuPROPion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May diminish the therapeutic effect of Levodopa-Foslevodopa.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Systemic): May decrease the serum concentration of Levodopa-Foslevodopa.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: May decrease the serum concentration of Levodopa. Only applies to oral iron preparations. Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: May diminish the therapeutic effect of Levodopa-Foslevodopa.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist). Kava Kava may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Levodopa-Foslevodopa may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methionine: May diminish the therapeutic effect of Levodopa-Foslevodopa. Management: Avoid large daily doses of methionine in patients receiving levodopa (clinical studies showing interaction used 4.5 g methionine daily). More typical doses of methionine (eg, 500 mg) may not cause a problem.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: Levodopa-Foslevodopa may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Type B): Levodopa-Foslevodopa may enhance the orthostatic hypotensive effect of Monoamine Oxidase Inhibitors (Type B). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May diminish the therapeutic effect of Levodopa-Foslevodopa. Management: Concurrent use of a multivitamin and levodopa (without carbidopa) should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May diminish the therapeutic effect of Levodopa. Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Levodopa. Only applies to oral iron-containing preparations. Management: Separate doses of these agents by 2 or more hours.  Monitor for decreased levodopa effects, particularly if doses cannot be separated.  Concurrent use of a multivitamin and levodopa (without carbidopa) should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May diminish the therapeutic effect of Levodopa-Foslevodopa. Management: Concurrent use of a multivitamin and levodopa (without carbidopa) should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Papaverine: May enhance the hypotensive effect of Levodopa-Foslevodopa. Papaverine may diminish the therapeutic effect of Levodopa-Foslevodopa.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pyridoxine: May diminish the therapeutic effect of Levodopa-Foslevodopa. Management: The concomitant use of pyridoxine and levodopa (in the absence of a dopa decarboxylase inhibitor (DDI)) should be avoided. Use of a DDI (eg, carbidopa) with levodopa will essentially eliminate the risk of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: Levodopa-Foslevodopa may enhance the hypotensive effect of Reserpine. Reserpine may diminish the therapeutic effect of Levodopa-Foslevodopa.  Management: Consider alternatives to the coadministration of levodopa and reserpine. If combined, monitor for reduced levodopa efficacy and hypotension.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sapropterin: May enhance the adverse/toxic effect of Levodopa-Foslevodopa.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors: May diminish the therapeutic effect of Levodopa-Foslevodopa. Management: Consider alternatives to the coadministration of levodopa and vesicular monoamine transporter 2 (VMAT2) inhibitors. If combined, monitor for reduced levodopa efficacy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F139713"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">High protein diets have the potential to impair levodopa absorption; levodopa competes with certain amino acids for transport across the gut wall or across the blood-brain barrier. Management: Avoid high protein diets.</p>
<p style="text-indent:-2em;margin-left:2em;">Food reduces the extent of levodopa absorption by 15% and peak plasma concentrations by 30%. Management: Administer with or immediately after meals.</p></div>
<div class="block rep_considerations drugH1Div" id="F49095581"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in women of childbearing potential not using proper contraception.</p></div>
<div class="block pri drugH1Div" id="F139703"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use is contraindicated during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Levodopa crosses the placenta and can be metabolized by the fetus and detected in fetal tissue (Merchant 1995). The incidence of Parkinson disease in pregnancy is relatively rare and information related to the use of benserazide/levodopa in pregnant women is limited (Hagell 1998; von Graevenitz 1996). The manufacturer recommends that women who become pregnant during therapy gradually taper off therapy; avoid abrupt withdrawal.</p></div>
<div class="block brc drugH1Div" id="F139704"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Levodopa is present in breast milk (based on a study using carbidopa/levodopa) (Thulin 1998); excretion of benserazide is not known. Breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block dic drugH1Div" id="F139705"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">High-protein diets may decrease effect of levodopa.</p></div>
<div class="block mop drugH1Div" id="F139692"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Regular assessment of cardiovascular, hepatic, hematopoietic, and renal function with initiation and during dose stabilization then periodically with extended therapy; blood glucose frequently in patients with diabetes; symptoms of psychosis and dystonia</p></div>
<div class="block pha drugH1Div" id="F139682"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Symptoms of Parkinson disease are due to a lack of striatal dopamine. Levodopa crosses into the blood-brain barrier (BBB) and is converted to dopamine by striatal enzymes. Benserazide inhibits the peripheral plasma breakdown of levodopa by inhibiting its decarboxylation and therefore increases levodopa availability at the BBB.</p></div>
<div class="block phk drugH1Div" id="F139699"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Benserazide: 66% to 74% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Benserazide: Does not cross the blood-brain barrier; mainly concentrated in kidneys, liver, lungs, and small intestine</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levodopa: 57 L; crosses the blood-brain barrier and not bound to plasma proteins</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Benserazide: Hydroxylated in the intestine and liver to trihydroxybenzylhydrazine, a potent inhibitor of decarboxylase</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levodopa: Major pathways: Decarboxylation to dopamine and O-methylation to 3-O-methyldopa; Minor pathways; Transamination and oxidation</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Levodopa: 98% (range: 74% to 112%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Levodopa: 1.5 hours; 3-O-methyldopa (major metabolite): 15 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Levodopa: ~1 hour </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Benserazide: Urine (64%); feces (24%); Levodopa: Urine (as metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F139706"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Madopar | Madopar hbs</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Madopar | Madopar cr | Restex</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Prolopa</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Madopar | Madopar hbs | Menkart</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ekson | Lebens | Levodopa + cloridrato de benserazida | Levrasida | Prolopa | Prolopa hbs</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Levodopa/benserazid devatis | Madopar | Madopar dr | Madopar hbs | Madopar LIQ 62.5</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Levibense | Madozide | Melitase | Prolopa</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">L-dopa+benserazide | Levodopa and benserazide hydrochloride | Madopar</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Levodopa benserazide Teva | Madopar | Madopar hbs</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dopadura B | Levobens Teva | Levodopa Benserazid beta | Levodopa benserazide | Levodopa Benserazide CT | Levodopa comp b | Levodopa plus benserazid AL | Levodopa/benserazid neuraxpharm | Levodopa/Benserazide Devatis | Levopar | Madopar | Madopar Depot | Madopar LT | Pk Levo | Prolopa | Restex</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Prolopa</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Madopar | Prolopa</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Aktipar | Madopar | Madopar hbs</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Aktipar | Levodopa/benserazide orifarm | Madopar</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Levodopa benserazide Teva | Modopar | Modopar lp</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Co-Beneldopa | Madopar</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Levodopa+benserazide/teva | Madopar | Madopar hbs</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Leparson | Levazide | Levoben | Levopar | Madopar | Madopar dispersible | Pardoz</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Levopar plus</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ec doparl | Madopar | Neodopasol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Madopar | Madopar hbs | Myungdopar | R.b.p</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Madopar | Madopar hbs</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Prolopa</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Madopar | Madopar hbs</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Madopar | Modopar</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Levodopa/Benserazide PCH | Madopar | Modopar</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Levodopa/benserazide | Madopar</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Hardal | Levosta | Madopar | Madopar hbs | Madozide</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Madopar | Madopar hbs</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Madopar | Madopar hbs</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Madopar | Madopar hbs | Madozide | Melitase | Prolopa | Prolopa hbs | Seler</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Levodopa/benserazide teva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Benziel | Levodopa benserazide | Levodopa/benserazide teva | Madopar | Madopar gss | Madopar hbs</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Levodopa/Benserazid Ebb | Levodopa/benserazid ratiopharm | Levodopa/benserazide 2care4 | Levodopa/benserazide orifarm | Madopar | Madopar Depot | Madopar Quick | Madopar Quick mite | Madopark | Madopark depot | Madopark quick</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Madopar | Madopar hbs</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Levopar | Madopar | Vopar</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Modopar</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bendopa | Bendopar | Madopar</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Levodopa C | Prolopa | Prolopa hbs | Seler | Tonotil</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Levobenserazid vmg</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Madopar</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-22851801">
<a name="22851801"></a>Aurora RN, Kristo DA, Bista SR, et al; American Academy of Sleep Medicine. The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine clinical practice guideline. <i>Sleep</i>. 2012;35(8):1039-1062. doi:10.5665/sleep.1988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/22851801/pubmed" id="22851801" target="_blank">22851801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10617168">
<a name="10617168"></a>Benes H, Kurella B, Kummer J, Kazenwadel J, Selzer R, Kohnen R. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. <i>Sleep</i>. 1999;22(8):1073-1081. doi:10.1093/sleep/22.8.1073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/10617168/pubmed" id="10617168" target="_blank">10617168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7876846">
<a name="7876846"></a>Collins SJ, Ahlskog JE, Parisi JE, Maraganore DM. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. <i>J Neurol Neurosurg Psychiatry</i>. 1995;58(2):167-173. doi:10.1136/jnnp.58.2.167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/7876846/pubmed" id="7876846" target="_blank">7876846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22937989">
<a name="22937989"></a>Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al; European Federation of Neurological Societies; European Neurological Society; European Sleep Research Society. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. <i>Eur J Neurol</i>. 2012;19(11):1385-1396. doi:10.1111/j.1468-1331.2012.03853.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/22937989/pubmed" id="22937989" target="_blank">22937989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27448465">
<a name="27448465"></a>Garcia-Borreguero D, Silber MH, Winkelman JW, et al Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. <i>Sleep Med</i>. 2016;21:1-11. doi:10.1016/j.sleep.2016.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/27448465/pubmed" id="27448465" target="_blank">27448465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18725592">
<a name="18725592"></a>Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. <i>Neurology</i>. 2008;71(9):670-676. doi:10.1212/01.wnl.0000324625.00404.15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/18725592/pubmed" id="18725592" target="_blank">18725592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10727476">
<a name="10727476"></a>Giovannoni G, O’Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. <i>J Neurol Neurosurg Psychiatry.</i> 2000;68(4):423-428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/10727476/pubmed" id="10727476" target="_blank">10727476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18823039">
<a name="18823039"></a>Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. <i>Mov Disord</i>. 2008;23(15):2248-2250. doi:10.1002/mds.22322<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/18823039/pubmed" id="18823039" target="_blank">18823039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31501181">
<a name="31501181"></a>Grimes D, Fitzpatrick M, Gordon J, et al. Canadian guideline for Parkinson disease. <i>CMAJ</i>. 2019;191(36):E989-E1004. doi:10.1503/cmaj.181504<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/31501181/pubmed" id="31501181" target="_blank">31501181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9452323">
<a name="9452323"></a>Hagell P, Odin P, and Vinge E. Pregnancy in Parkinson's disease: a review of the literature and a case report. <i>Mov Disord</i>. 1998;13(1):34-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/9452323/pubmed" id="9452323" target="_blank">9452323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2900293">
<a name="2900293"></a>Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. <i>J Neurol Neurosurg Psychiatry</i>. 1988;51(6):850-854. doi:10.1136/jnnp.51.6.850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/2900293/pubmed" id="2900293" target="_blank">2900293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28467028">
<a name="28467028"></a>Höglinger GU, Respondek G, Stamelou M, et al; Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. <i>Mov Disord</i>. 2017;32(6):853-864. doi:10.1002/mds.26987<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/28467028/pubmed" id="28467028" target="_blank">28467028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9678313">
<a name="9678313"></a>Kompoliti K, Goetz CG, Boeve BF, et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. <i>Arch Neurol</i>. 1998;55(7):957-961. doi:10.1001/archneur.55.7.957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/9678313/pubmed" id="9678313" target="_blank">9678313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20584946">
<a name="20584946"></a>Ling H, O'Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. <i>Brain</i>. 2010;133(pt 7):2045-2057. doi:10.1093/brain/awq123<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/20584946/pubmed" id="20584946" target="_blank">20584946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26025783">
<a name="26025783"></a>Low PA, Reich SG, Jankovic J, et al. Natural history of multiple system atrophy in the USA: a prospective cohort study. <i>Lancet Neurol</i>. 2015;14(7):710-719. doi:10.1016/S1474-4422(15)00058-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/26025783/pubmed" id="26025783" target="_blank">26025783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-497698">
<a name="497698"></a>Massarotti G, Cassi E, Passaleva A. Lupus-like autoimmune syndrome after levodopa and benserazide. <i>Br Med J</i>. 1979;2(6189):553. doi:10.1136/bmj.2.6189.553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/497698/pubmed" id="497698" target="_blank">497698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8527007">
<a name="8527007"></a>Merchant CA, Cohen G, Mytilineou C, et al. Human transplacental transfer of carbidopa/levodopa. <i>J Neural Transm Park Dis Dement Sect.</i> 1995;9(2-3):239-422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/8527007/pubmed" id="8527007" target="_blank">8527007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11009192">
<a name="11009192"></a>Molina JA, Sàinz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment. <i>Mov Disord. </i>2000;15(5):869-872.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/11009192/pubmed" id="11009192" target="_blank">11009192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16107351">
<a name="16107351"></a>Molloy S, McKeith IG, O'Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. <i>J Neurol Neurosurg Psychiatry</i>. 2005;76(9):1200-1203. doi:10.1136/jnnp.2004.052332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/16107351/pubmed" id="16107351" target="_blank">16107351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oliver.1">
<a name="Oliver.1"></a>Oliver D, Veronese S. Palliative approach to Parkinson disease and parkinsonian disorders. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 31, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prolopa.1">
<a name="Prolopa.1"></a>Prolopa (levodopa/benserazide) [product monograph]. Mississauga, Ontario, Canada: Hoffman-La Roche Limited; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12573874">
<a name="12573874"></a>Serrano-Dueñas M. Neuroleptic malignant syndrome-like, or--dopaminergic malignant syndrome--due to levodopa therapy withdrawal. Clinical features in 11 patients. <i>Parkinsonism Relat Disord</i>. 2003;9(3):175-178. doi:10.1016/s1353-8020(02)00035-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/12573874/pubmed" id="12573874" target="_blank">12573874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9633767">
<a name="9633767"></a>Thulin PC, Woodward WR, Carter JH, et al. Levodopa in human breast milk: clinical implications. <i>Neurology</i>, 1998;50(6):1920-1921.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/9633767/pubmed" id="9633767" target="_blank">9633767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19252795">
<a name="19252795"></a>Tinazzi M, Antonini A, Bovi T, et al. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. <i>J Neurol</i>. 2009;256(6):910-915. doi:10.1007/s00415-009-5039-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/19252795/pubmed" id="19252795" target="_blank">19252795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8771087">
<a name="8771087"></a>von Graevenitz KS, Shulman LM, and Revell SP. Levodopa in pregnancy. <i>Mov Disord.</i> 1996;11(1):115-116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/8771087/pubmed" id="8771087" target="_blank">8771087</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9796 Version 200.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
